NASDAQ: BLFS · Medical Instruments & Supplies
BioLife Solutions (BLFS) fair value: undervalued or overvalued?
As of 26 Sep 2026, Faircurve's model values BioLife Solutions (BLFS) at $33.70 a share. The stock last closed at $37.30, which puts the model's fair value 9.7% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. BioLife Solutions, Inc.
Faircurve Insights · 26 Sep 2026
BioLife Solutions, Inc. operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry.
Faircurve's model found a fair value of $33.70 a share on 26 Sep 2026. This is the midpoint of 2,000 simulations. The previous run, on 19 Sep 2026, gave $34.06, a move of -1.1%. The calibrated range over 63 trading days is $28.27 to $41.09, built from the fair value. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as Medium.
The overall quality score is 48 out of 100, against comparable companies. These include LeMaitre Vascular, Inc., ICU Medical, Inc., Merit Medical Systems, Inc., and AptarGroup, Inc. Moves around the last 8 earnings reports had a median size, ignoring direction, of 5.8%.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give BLFS?
The calibrated range for BLFS over 63 trading days is $28.27 to $41.09. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $27.73 to $40.77. In 27% of the simulations the fair value came out above the price the model ran on.
How does BLFS score on business quality?
BioLife Solutions's overall quality score is 48 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 52 | 1.8%ROIC | -0.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 4 | -0.02xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 67 | 17.0%Revenue growth, trailing | 3.4% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 28 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 84 | -0.84xNet debt / EBITDA | 4.02x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 69 | 5.2 ptsEBITDA margin downside volatility, 5y | 12.7 pts |
How does BLFS compare with similar companies?
The companies in medical instruments & supplies closest to BioLife Solutions in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| XRAY DENTSPLY SIRONA Inc. | $8.67 | $15.20 | +75.3% | Gap wider than 60% |
| LMAT LeMaitre Vascular, Inc. | $78.96 | $76.10 | -3.6% | Fairly valued |
| STAA STAAR Surgical Company | $22.47 | $20.55 | -8.5% | Low evidence grade |
| NVST Envista Holdings Corp | $23.46 | $23.26 | -0.9% | Low evidence grade |
| ICUI ICU Medical, Inc. | $159.38 | $191.03 | +19.9% | Undervalued |
| MMSI Merit Medical Systems, Inc. | $85.37 | $88.67 | +3.9% | Fairly valued |
| TFX Teleflex Incorporated | $124.12 | $125.37 | +1.0% | Low evidence grade |
| ATR AptarGroup, Inc. | $119.91 | $120.42 | +0.4% | Fairly valued |
All medical instruments & supplies stocks ranked by gap to fair value
When does BLFS report earnings, and how has the stock reacted?
BioLife Solutions's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
Options prices on 29 Sep 2026 imply a move of about 16.4% in either direction through the nearest expiry, about 51 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How BLFS moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 5.8%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | +2.5% |
| 7 May 2026 | +1.3% |
| 26 Feb 2026 | +7.7% |
| 6 Nov 2025 | -5.9% |
| 7 Aug 2025 | +7.5% |
| 8 May 2025 | -5.6% |
| 3 Mar 2025 | +3.5% |
| 12 Nov 2024 | -9.4% |
BioLife Solutions at a glance
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry.
- Market value
- $1.9B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $129M
- Consensus revenue growth, next fiscal year
- +19.2%
- Analysts with estimates
- 1
- Beta to the US market
- 0.98
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices BioLife Solutions on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for BLFS was $34.06. As of 26 Sep 2026 it is $33.70, a change of -1.1%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about BioLife Solutions's valuation
Is BioLife Solutions stock undervalued or overvalued?
On Faircurve's model, BLFS reads as Fairly valued as of 26 Sep 2026. The model's fair value is $33.70 a share against a last close of $37.30, a gap of -9.7%.
What is BLFS's fair value?
$33.70 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $27.73 to $40.77.
What price range does the model give BLFS?
$28.27 to $41.09 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does BioLife Solutions report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has BLFS moved on past earnings reports?
Across its last 8 reports the median two session move was 5.8%, ignoring direction. The largest was -9.4% around the report of 12 Nov 2024.
How confident is the model in this valuation?
The model's evidence grade for BLFS is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.